Latest Industry Insights

To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

In this interview, we speak to Alon Ben-Noon, CEO and co-founder of Neurosense Therapeutics to hear about the impact their drug development strategy is having on the ALS field.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

PerkinElmer announced the launch of a new automated gas chromatography, the GC 2400 Platform. We spoke to Suneet Chadha to learn more about this latest introduction.